Isomorphic Labs announced what it called a major advance in its AI drug‑design engine after rolling out AlphaFold‑derived models in prior years; the company claims enhanced capability to convert structural predictions into design candidates. Exact technical details and peer validation remain limited in the public release. China‑focused Insilico Medicine and CMS (China Medical System) announced multiple collaborations to apply AI across CNS and autoimmune R&D. Together these moves highlight accelerating industry investment in computational discovery and multi‑partner alliances aimed at compressing early discovery timelines.